Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Maze Therapeutics, Inc. announced that its Board appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, effective August 13, 2026. Dr. Johnson’s term runs to the 2028 annual stockholders’ meeting and Dr. Kornowski’s to 2029, each continuing until a successor is elected or earlier departure events occur. Dr. Johnson joins the nominating and corporate governance committee, while Dr. Kornowski joins the audit and compensation committees.
Each new non-employee director receives compensation under Maze’s director policy, including a pro rata portion of the $40,000 annual cash retainer plus applicable committee retainers and an option to purchase 36,000 shares of common stock, vesting in equal monthly installments over 36 months from the appointment date. The Board also reclassified existing directors Nancy C. Andrews, M.D., Ph.D. and Hervé Hoppenot between Class II and Class III to rebalance the three director classes, with revised terms expiring at the 2027 and 2028 annual meetings, respectively.
Maze Therapeutics, Inc. officer Harold Bernstein (President, R&D & CMO) exercised stock options and sold shares on August 13, 2026 under a Rule 10b5-1 trading plan adopted on September 29, 2025. He exercised options for 16,142 shares of common stock at an exercise price of $10.42 per share, reducing that option position and leaving 176,803 options outstanding from this award. The resulting 16,142 common shares were then sold at a weighted average price of $27.6063 per share, in multiple trades between $27.17 and $28.00. The options vest over four years, with 1/4 vested on October 3, 2023 and the remainder in equal monthly installments, conditioned on continued service.
Maze Therapeutics, Inc. received an amended Schedule 13G/A from a group of Paradigm BioCapital-affiliated investors reporting that they no longer beneficially own Common Stock of the company. The amendment is effective as of the close of business on June 30, 2026.
The Reporting Persons — Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. — each report 0.00 shares beneficially owned and 0.0% of the Common Stock, with no sole or shared voting or dispositive power. They note that any prior holdings were directly owned by the Fund and certain separately managed accounts, and each party disclaims beneficial ownership except for securities directly held by it.
Maze Therapeutics, Inc. reported unaudited results for the quarter and six months ended June 30, 2026, reflecting continued investment in its kidney and metabolic disease pipeline. Cash, cash equivalents and marketable securities totaled $494.9 million, supported by a recent underwritten equity offering and a new term loan facility.
For the first half of 2026, Maze recorded $20.0 million of license revenue from a clinical milestone under its Shionogi agreement and a net loss of $68.9 million, compared with a $66.5 million net loss a year earlier. Research and development expenses rose to $69.1 million and general and administrative expenses to $25.5 million, driven by clinical trials for lead programs MZE829 (APOL1-mediated kidney disease) and MZE782 (phenylketonuria and chronic kidney disease).
Total assets were $531.6 million and total liabilities $78.5 million, including a newly funded $40.0 million tranche under a Hercules senior secured term loan facility of up to $200.0 million. Maze also put in place a $200.0 million at-the-market stock offering program, with no sales to date, and believes its current capital will fund operations for at least one year from the financial statement issuance date.
Maze Therapeutics, Inc. reported second quarter 2026 results and pipeline updates. The company is advancing Phase 2 programs for MZE829 in APOL1-mediated kidney disease and MZE782 in phenylketonuria and chronic kidney disease, with multiple data readouts and a pivotal trial for MZE829 planned from late 2026 through 2027, subject to regulatory feedback.
Maze reported a net loss of $44.7 million for the quarter, or $0.76 per share$494.9 million as of June 30, 2026, supported by an April 2026 equity and pre-funded warrant offering of approximately $150 million in gross proceeds. Maze states that this cash position is expected to fund operations into 2029.
Maze Therapeutics, Inc. Chief Executive Officer Jason V. Coloma reported indirect sales totaling 34,501 shares of common stock on August 3, 2026. Shares held by The Coloma 2021 Irrevocable Trust and the Coloma Family Trust, for which Coloma and his spouse are co‑trustees, were sold in four non‑derivative transactions at weighted average prices of $26.7145, $27.0940, $26.7140, and $27.0853 per share, executed pursuant to a Rule 10b5‑1 trading plan adopted on February 6, 2026.
MAZE received a Form 144 notice covering proposed sales of its common stock. A brokerage account at UBS Financial Services is listed for up to 34,501 shares of common stock, with an indicated value of $922,556.74, and 55,345,261 shares of common stock outstanding as of 08/03/2026 on Nasdaq. The notice also lists prior transactions, including gifts of 2,593 and 31,908 common shares on 09/22/2021 from earlier acquisitions in 2018 and 2019. During the past three months, the Coloma Family Trust and The Coloma 2021 Irrevocable Trust reported several open-market sales of MAZE common stock on dates in May, June, and July 2026, each with specific share counts and dollar amounts.
Maze Therapeutics, Inc. officer Atul Dandekar reported exercising stock options for 7,500 shares of common stock at an exercise price of $10.42 per share and selling 7,500 shares of common stock in multiple transactions at weighted-average prices of $27.3064 and $27.89. These transactions were effected under a Rule 10b5-1 trading plan adopted on September 29, 2025. The fully vested option, which expires on April 11, 2031, left 21,643 options outstanding after the exercise.
MAZE shareholder Atul Dandekar filed to sell up to 22,500 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an anticipated transaction date of 07/29/2026 on NASDAQ following an exercise of stock options for cash. The filing also lists prior 10b5-1 sales of 7,500 shares on 06/29/2026 for $210,150.00 and 7,500 shares on 05/29/2026 for $197,553.75.
BlackRock, Inc. reports a passive ownership stake in Maze Therapeutics Inc. common stock. BlackRock and certain of its subsidiaries and affiliates beneficially own 2,978,114 shares of Maze common stock, representing 5.4% of the outstanding class as of the reporting date.
BlackRock has sole voting power over 2,922,889 shares and sole dispositive power over all 2,978,114 shares, with no shared voting or dispositive power. Various underlying clients and funds have rights to dividends or sale proceeds from these securities, but no single client holds more than five percent of Maze’s total outstanding common shares.